Clinical Trial

Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions

Study acronym: PROCEM
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Patients diagnosed with breast cancer after routine assessment with digital mammography and ultrasound and scheduled for primary surgery are included in the trial. The patients are randomized 1:1 to go through additional contrast enhanced mammography (CEM) or no further imaging preoperatively. Primary endpoint is rate of patients with change of treatment: a) mastectomy instead of partial mastectomy due larger unifocal or multifocal extent, b) partial mastectomy instead of mastectomy due to improved demarcation of the tumour area, c) bilateral surgery instead of unilateral due to findings of contralateral cancer, d) neoadjuvant therapy instead of primary surgery due to more advanced disease. Rate of reoperation and rate of avoidable mastectomies are secondary endpoints.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-17; most recent amendment 2024-05-06.
Status change: Recruiting → Active, Not Recruiting 2024-05-06
Status change: Not Yet Recruiting → Recruiting 2020-11-04
Trial Details
NCT Number NCT04437602
Lead Sponsor Region Halland
Conditions Breast Cancer
Enrollment 441 participants
Start Date 2020-11-02
Primary Completion 2024-04-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-07